Safety and Efficacy of BAF312 in Dermatomyositis

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Novartis
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: December 2, 2013
Last updated: February 17, 2015
Last verified: February 2015

This study investigates the dose response relationship for the efficacy and safety of BAF312 compared to placebo in active DM patients over a treatment period of 6+6 months and to determine the minimum dose required for a maximal clinical effect. The study is composed of 2 periods: a double-blind period I with BAF312 administered at different daily doses (0.5, 2, 10 mg and placebo) and a fixed-dose Period II in which BAF312 will be administered at the dose of 2 mg daily .

Condition Intervention Phase
Active Dermatomyositis
Drug: BAF312 0.5 mg
Drug: BAF312 2 mg
Drug: BAF312 10 mg
Drug: Placebo to BAF312
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Manual Muscle Testing -8 muscles (MMT-8). Efficacy of BAF312 will be assessed by comparing the improvements with every dose of BAF312 to that of placebo. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    The primary aim of this study is to assess the efficacy of different doses of BAF312 on the MMT-8 after 6 months. The overall efficacy of BAF312 will be assessed by comparing the improvements of MMT-8 with every dose of BAF312 to that of placebo. Then the doseresponse curve of MMT-8 will be estimated with the aim to determine a target dose for the program.

Secondary Outcome Measures:
  • Adverse Events. All information obtained on adverse events will be displayed by treatment (dose group) and subject. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Secondary variables include the incidence of adverse events.

  • Pharmacokinetics. BAF312 plasma concentration data will be listed by treatment (dose group), subject and visit/sampling time point. Descriptive summary statistics will be provided by treatment and visit/sampling time point. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Secondary variables include plasma BAF312 concentrations.

  • Peripheral blood lymphocyte counts. Absolute lymphocyte counts will be plotted against time by dose level. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Secondary variables include peripheral blood lymphocyte counts.

  • Manual Muscle Testing-8 muscles (MMT-8). Efficacy of BAF312 will be assessed by comparing the improvements with every dose of BAF312 to that of placebo. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Changes from baseline in MMT-8 at 3 months will also be evaluated. The dose-response will be assessed in the same way as for the 6-month data.

Estimated Enrollment: 56
Study Start Date: November 2013
Estimated Study Completion Date: April 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BAF312 0.5mg
BAF312 0.5 mg/day
Drug: BAF312 0.5 mg
BAF312 0.5 mg once daily
Experimental: BAF312 2mg
BAF312 2 mg/day
Drug: BAF312 2 mg
BAF312 2 mg once daily
Experimental: BAF312 10 mg
BAF312 10 mg/day
Drug: BAF312 10 mg
BAF312 10 mg once daily
Placebo Comparator: Placebo
Drug: Placebo to BAF312
Placebo to BAF312 once daily


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed.

  • Patients who have been defined as "definite" or "probable" based on the criteria of Bohan and Peter (Bohan and Peter 1975) for dermatomyositis at least 12 months before screening
  • Patients must have active disease as defined by dermatomyositis skin rash AND Muscle weakness
  • Patients must have responded inadequately to previous standard of care or have demonstrated significant toxicity or intolerance to such therapies.
  • Patients may be on a stable dose of corticosteroid (up/equal to 20 mg once daily prednisone equivalent)
  • Patients currently treated with oral or subcutaneous MTX must have been a stable dose of no more/equal to than 25 mg per week
  • Patients currently treated with Azathioprine must have been a stable maintenance dose of no more/equal to 3 mg/kg/day
  • Negative cancer screening conducted in the 6 months prior to screening visit

Exclusion Criteria

  • Dermatomyositis patients having overlap myositis or any other type of myositis including paraneoplastic myositis, drug-induced myopathy, necrotizing myositis
  • Preexisting severe cardiac or pulmonary conditions, malignancy of any organ system or significant eye diseases.
  • Uncontrolled diabetes mellitus or diabetes complicated with organ involvement.
  • Pregnant or nursing (lactating) women
  • Other protocol-defined inclusion/exclusion criteria apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02029274

Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals

  Show 30 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT02029274     History of Changes
Other Study ID Numbers: CBAF312X2206, 2013-001799-39
Study First Received: December 2, 2013
Last Updated: February 17, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Novartis:

Additional relevant MeSH terms:
Polymyalgia Rheumatica
Connective Tissue Diseases
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Rheumatic Diseases
Skin Diseases processed this record on March 26, 2015